Dermatology Immune Response Medicine 
Scienmag
MARCH 3, 2021
Results could lead to better drugs used to fight inflammation At the beginning of an immune response, a molecule known to mobilize immune cells into the bloodstream, where they home in on infection sites, rapidly shifts position, a new study shows.
pharmaphorum
SEPTEMBER 29, 2022
The disorder – driven by type 2 inflammation characterised by an antibody-based immune response – causes hard lumps or nodules to form on the skin that are so itchy they can lead patients to scratch themselves to the point of bleeding or pain.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
AUGUST 16, 2021
Fast Track designation is granted for a medicine that is intended to treat a serious condition and data demonstrate the potential to address an unmet medical need. AD, also known as atopic eczema, is a chronic inflammatory skin disorder caused by skin barrier dysfunction and dysregulation of the immune response.
The Pharma Data
JUNE 19, 2022
Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, they can wear out and cease to function. They conducted their first experiment with cultured mouse melanoma cells.
The Pharma Data
OCTOBER 9, 2021
Ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), is characterized by an irregular, chronic immune response that creates inflammation and ulcers (sores) in the mucosa (lining) of the large intestine (colon) or rectum. Deucravacitinib is not approved for use in any country. About Ulcerative Colitis.
The Pharma Data
APRIL 28, 2021
These and other data from real-world settings and clinical trials, including the Dupixent open-label extension (OLE) trials, will be presented at the American Academy of Dermatology (AAD VMX 2021), April 23-25, and at the 20 th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021), May 12-14.
The Pharma Data
MARCH 16, 2021
These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021. Click to Tweet: New Phase 3 study shows efficacy and safety data at two years with Janssen’s medicine in patients with active #PsA. Read more: [link]. o chest tightness.
Expert insights. Personalized for you.
57 
Let's personalize your content